FDA Approves Drug That Extends Survival in the Most Common Type of Lung Cancer
Friday, December 12, 2014 - 16:00
in Health & Medicine
FDA has approved the drug Cyramza, to be used in combination with docetexal for the treatment of non-small-cell lung cancer (NSCLC).